[Form 4] Nautilus Biotechnolgy, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Matthew B. Murphy, listed as General Counsel and Trustee of the Murphy Family Trust, reported transactions in Nautilus Biotechnology, Inc. (NAUT) on 09/04/2025.

He purchased 20,000 shares of Nautilus common stock at $0.6429 per share and disposed of 1,250 shares on the same transaction date. After the reported purchase, the filing shows beneficial ownership of 74,140 shares held indirectly through the Murphy Family Trust.

Positive

• Insider purchase disclosed of 20,000 shares at $0.6429, increasing reported indirect holdings to 74,140 shares
• Timely filing and signature (transaction dated 09/04/2025, signed 09/05/2025) demonstrating compliance with Section 16 reporting

Negative

• Small disposal of 1,250 shares was also reported, partially offsetting purchased shares

Insights

Securities Analyst

TL;DR: Insider purchased a modest number of shares; net indirect holdings increased to 74,140 shares.

From a trading perspective, the acquisition of 20,000 shares at $0.6429 is a modest insider buy and increases the reporting persons indirect stake held in the Murphy Family Trust to 74,140 shares. The disposal of 1,250 shares partially offsets the purchase but is small relative to the acquired amount. These transactions are routine disclosures under Section 16 and do not, by themselves, convey material corporate events.

Corporate Governance Expert

TL;DR: Transaction is clearly disclosed; trustee status and officer role are noted, supporting governance transparency.

The filing identifies Matthew B. Murphy as both an officer (General Counsel) and the Trustee of the Murphy Family Trust, which holds the indirectly owned shares. The Form 4 properly reports both acquisition and disposition activity on 09/04/2025 and includes a signature dated 09/05/2025. This disclosure aligns with Section 16 requirements and supports timely insider reporting practices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Matthew B.

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2025		P		20,000	A	$0.6429	74,140	I	See Footnote(1)
Common Stock								1,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust.

Remarks:

	/s/ Matthew B. Murphy	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Matthew B. Murphy purchase in Nautilus (NAUT)?

He purchased 20,000 shares of Nautilus common stock at $0.6429 per share on 09/04/2025.

How many Nautilus shares does the Murphy Family Trust beneficially own after the transaction?

The Form 4 reports 74,140 shares as beneficially owned indirectly through the Murphy Family Trust.

Was there any disposition by the reporting person?

Yes, the filing reports a disposal of 1,250 shares (reported on the same transaction date).

What is Matthew B. Murphys role at Nautilus?

He is reported as an Officer (General Counsel) and is the Trustee of the Murphy Family Trust.

When was the Form 4 signed?

The Form 4 bears a signature dated 09/05/2025.